Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie

Showing 15 posts of 235 posts found.

abbviehqe_004_low

AbbVie’s experimental cancer drug hits wall in clinical study

April 20, 2017
Research and Development AbbVie, AstraZeneca

AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary endpoints. …

News
abbvie_0

UK High Court rules against AbbVie’s Humira patents

March 6, 2017
Sales and Marketing AbbVie, Biogen, Fujifilm Kyowa Kirin Biologics, Humira, Samsung Bioepis, biosimilar

The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and …

News
abbvie_0

NICE rejects AbbVie’s leukaemia drug

February 16, 2017
Sales and Marketing AbbVie

NICE has rejected AbbVie Venclyxto (venetoclax) for the treatment of chronic lymphocytic leukmaemia, on various grounds but primarily focusing upon …

News
u_of_liverpool

Major pharma firms join Liverpool Uni in £14m pharmacovigilance project

January 30, 2017
Research and Development, Sales and Marketing AZ, AbbVie, Eli Lilly, GSK, University of Liverpool, pharmacovigilance

The UK’s University of Liverpool is to launch a £14 million pharmacovigilance project focused on using new modelling approaches to …

News
ema_building_2

Amgen drug pair become first Humira biosimilars to win EU approval

January 30, 2017
Sales and Marketing AbbVie, Amgen, Amgevita, Humira, Solymbic, rheumatoid arthritis

Good news for Amgen as its two biosimilar versions of AbbVie’s blockbuster rheumatoid arthritis (RA) drug Humira (adalimumab) have been …

News
imbruvica_logo_0

NICE approves Imbruvica for second-line leukaemia treatment

January 26, 2017
Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica

NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …

News
abbvie_0

EMA Accelerated Assessment for AbbVie’s hepatitis C regimen

January 24, 2017
Manufacturing and Production, Research and Development AbbVie, EMA, hepatitis C

AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency …

News
abbvie_0

European thumbs up for Abbvie leukaemia drug

December 8, 2016
Medical Communications, Sales and Marketing AbbVie, Venclyxto

Abbvie has confirmed its Venclyxto (venetoclax) has been granted marketing authorisation by the European Commission (EC) as a monotherapy for …

News
imbruv_pack

Janssen reveals positive results from longest follow-up of Imbruvica

December 7, 2016
Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica

Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …

News
humira_abbott_

Humira biosimilar proves efficacy in Phase 3 trial

November 30, 2016
Research and Development AbbVie, Amgen, FDA, Humira, M923, Momenta

US-based biotechnology firm Momenta Pharmaceuticals has announced that its biosimilar version of Abbvie’s autoimmune drug Humira (adalimumab) – currently the …

News
abbvie_0

AbbVie investigational hep C drug boasts 97.5% response rate

November 15, 2016
Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic

AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …

News
abbott_humira

Coherus knocked back by AbbVie’s Humira patent protection

November 8, 2016
Manufacturing and Production, Sales and Marketing AbbVie, Coherus, Humira

Coherus Biosciences, a developer of biosimilars, has suffered a blow in their petition for Inter Partes Review (IPR) of one …

News
clinical_trial-web

Tesaro’s ovarian cancer drug success threatens market rivals

October 12, 2016
Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …

News
jj_2johnson_and_johnson

J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial

October 3, 2016
Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab

Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …

News
abbvie-singapore

AbbVie opens its $300 million manufacturing plant in Singapore

September 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore

AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026